Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Summary

Elevation Oncology (Nasdaq: ELEV) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Joseph J. Ferra, President and Chief Executive Officer, will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. ET. The company, which specializes in developing selective cancer therapies for patients with solid tumors, will provide a live webcast of the event, accessible through their Investor Relations website. A replay will also be available for those unable to attend the live presentation.

BOSTON, Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36^th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET.

A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion portion of a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact

Gracie Tong
Senior Director, Investor Relations and Corporate Communications
gtong@elevationoncology.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-302314303.html

SOURCE Elevation Oncology

FAQ

When is Elevation Oncology (ELEV) presenting at the Piper Sandler Healthcare Conference 2024?

Elevation Oncology (ELEV) will present at the Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. ET.

How can I watch Elevation Oncology's (ELEV) presentation at the Piper Sandler Conference?

You can watch the presentation through a live webcast available on Elevation Oncology's Investor Relations website at investors.elevationoncology.com. A replay will also be available after the event.

What type of presentation will Elevation Oncology (ELEV) give at the Piper Sandler Conference?

Elevation Oncology's CEO Joseph J. Ferra will participate in a fireside chat format presentation at the conference.

Which Elevation Oncology (ELEV) executive is presenting at the Piper Sandler Healthcare Conference?

Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will be presenting at the conference.